Stoke Therapeutics, Inc. STOK Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Global Development Activity | $4.03M+146% | $5.97M— | $6.68M— | $3.2M— | $1.64M— | |
| IP License | $0-100% | $0— | $0— | $0— | $150.78M— | |
| Operating Expenses by Product | ||||||
| ADOA | -$1.86M-54.8% | -$1.6M-23.7% | -$1.61M-11.8% | -$1.75M+40.9% | -$1.2M+30.3% | |
| MECP2 | $0+100% | $0+100% | -$16K+95.0% | $200K+179% | -$147K+39.3% | |
| Other External Program Costs | -$3.18M-73.8% | -$2.95M+0.2% | -$2.22M-28.8% | -$1.84M+10.2% | -$1.83M+10.5% | |
| Other Non Program Costs Research And Development | -$1.68M-19.4% | -$1.41M-75.3% | -$1.71M-7.9% | -$1.62M-9.8% | -$1.41M+3.6% | |
| Other Non Program Costs Sales General And Administrative | -$5.16M-7.7% | —— | -$4.59M-39.1% | —— | -$4.79M— | |
| Payroll And Other Personnel Costs Research And Development | -$16.12M-46.4% | -$16.45M-57.4% | -$12.63M-30.4% | -$11.62M-26.9% | -$11.01M-34.9% | |
| Payroll And Other Personnel Costs Sales General And Administrative | -$11.06M-23.8% | —— | -$8.94M-2.5% | —— | -$8.93M— | |
| SYNGAP1 | -$745K-118% | -$1.26M-217% | -$917K-130% | -$818K-242% | -$342K-20.4% | |
| Zorevunersen | -$19.85M-12.3% | -$21.69M-165% | -$21.09M-173% | -$11.38M-55.8% | -$17.67M-101% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stoke Therapeutics, Inc. break its business down?
- Stoke Therapeutics, Inc. (STOK) reports revenue by product across 4 parts — Global Development Activity, IP License, License and Service. Each is extracted from the segment footnotes and tracked over time.
- Where does Stoke Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stoke Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.